Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.BioVex Inc, a privately held biotechnology company, has raised $40 million in the first close of a Series F private financing.
Subscribe to our email newsletter
The placement was led by Forbion Capital Partners, who were joined by other existing investors including Credit Agricole Private Equity, Harris & Harris Group, Innoven Partners, New Science Ventures, Triathlon Medical Venture Partners and Scottish Equity Partners.
Philip Astley-Sparke, president and CEO of BioVex, said: “Following the unprecedented number of durable complete remissions generated with our lead cancer product, OncoVEX GM-CSF in a Phase II study in metastatic melanoma, the funds will be used to commence a pivotal Phase III study.
“The board is currently examining a number of options to raise a further $20 million to fund preparations for a biologics license application filing following the generation of Phase III data in 2010.”